ROLLA, Simona
 Distribuzione geografica
Continente #
NA - Nord America 3.569
EU - Europa 2.170
AS - Asia 881
AF - Africa 70
SA - Sud America 27
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 13
Totale 6.751
Nazione #
US - Stati Uniti d'America 3.514
IT - Italia 484
CN - Cina 462
DE - Germania 315
SE - Svezia 311
IE - Irlanda 253
FR - Francia 153
UA - Ucraina 143
SG - Singapore 113
FI - Finlandia 112
VN - Vietnam 86
GB - Regno Unito 82
KR - Corea 68
PL - Polonia 62
AT - Austria 61
DK - Danimarca 57
SN - Senegal 53
IN - India 45
CA - Canada 43
ES - Italia 28
GR - Grecia 25
JP - Giappone 24
BE - Belgio 21
NL - Olanda 18
TR - Turchia 18
IR - Iran 16
TW - Taiwan 15
AU - Australia 14
BR - Brasile 13
EU - Europa 12
MX - Messico 12
IL - Israele 11
CZ - Repubblica Ceca 7
HK - Hong Kong 7
NZ - Nuova Zelanda 7
RU - Federazione Russa 7
CO - Colombia 6
NO - Norvegia 6
RO - Romania 6
MU - Mauritius 5
CH - Svizzera 4
EG - Egitto 4
UZ - Uzbekistan 4
LB - Libano 3
MK - Macedonia 3
UY - Uruguay 3
ZA - Sudafrica 3
AR - Argentina 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
EC - Ecuador 2
EE - Estonia 2
HU - Ungheria 2
ID - Indonesia 2
PK - Pakistan 2
RS - Serbia 2
TN - Tunisia 2
A1 - Anonimo 1
CL - Cile 1
DZ - Algeria 1
HR - Croazia 1
JO - Giordania 1
MD - Moldavia 1
NP - Nepal 1
PT - Portogallo 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 6.751
Città #
Chandler 607
Beijing 269
Ann Arbor 263
Dublin 249
Ashburn 183
Fairfield 177
Houston 176
Fremont 159
Torino 127
Wilmington 108
Dearborn 106
Nyköping 100
Woodbridge 94
Jacksonville 89
Medford 88
Villeurbanne 82
Princeton 80
Turin 75
Dong Ket 72
Seattle 72
Cambridge 64
Vienna 61
Warsaw 58
Singapore 52
Redwood City 51
Milan 43
Pisa 38
Boardman 33
Washington 28
New York 27
Guangzhou 24
Boston 22
San Diego 22
Toronto 20
Nanjing 16
Shanghai 16
Brussels 15
Falls Church 15
San Mateo 14
Taipei 14
Hangzhou 11
Hefei 11
Los Angeles 11
Mountain View 11
Norwalk 11
Kunming 9
Nürnberg 9
Rome 9
Tokyo 9
Wuhan 9
Chengdu 8
Ottawa 8
Amsterdam 7
Dallas 7
Duncan 7
Düsseldorf 7
Helsinki 7
Menlo Park 7
Coventry 6
Hebei 6
Istanbul 6
Jinan 6
Munich 6
Phoenix 6
Tejupilco de Hidalgo 6
Alessandria 5
Des Moines 5
Kharkiv 5
Kozani 5
Madrid 5
Stavanger 5
Bergamo 4
Central District 4
Florence 4
Frankfurt am Main 4
Heidelberg 4
Leawood 4
Montreal 4
Montréal 4
Málaga 4
Netanya 4
Oldenburg 4
Paris 4
Pune 4
Seoul 4
Sevilla 4
Shibin al Kawm 4
Silver Spring 4
Stockholm 4
Upper Marlboro 4
Aci Catena 3
Brno 3
Cankaya 3
Canzo 3
Chicago 3
Cork 3
Curitiba 3
Gazi 3
Hamilton 3
Jerusalem 3
Totale 4.145
Nome #
Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer. 415
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis 375
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 308
Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells 203
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 177
Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. 169
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 166
D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient 160
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study 149
In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain 146
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 143
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 135
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 132
The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View 130
Natalizumab in Multiple Sclerosis: Long-Term Management 129
CHARACTERIZATION OF AUTOREACTIVE TCR REPERTOIRE IN PATIENTS AFFECTED BYMULTIPLE SCLEROSIS. 125
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 113
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta 109
DNA vaccination with alpha-enolase effectively prolongs survival in amouse model of human pancreatic cancer. 104
Computational modeling of the immune response in multiple sclerosis using epimod framework 103
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions 93
THE ACUTE-PHASE PROTEIN HEMOPEXIN IS A NEGATIVE REGULATOR OF TH17 RESPONSE AND EXPERIMENTAL AUTOIMMUNE ENCEPHALOMIELITIS DEVELOPMENT 92
The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice 92
T HELPER 22 CELLS INCREASE IN MULTIPLE SCELROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 88
THE BLOCKADE OF PLASMINOGEN-ALPHA-ENOLASE INTERACTION INHIBITS THE INVASION OF PANCREATIC CANCER CELLS. 87
Erbb2 DNA vaccine combined with Treg cell deletion enhances antibody response and reveals latent low-avidity T cells. Potential and limits of its therapeutic efficacy. 87
Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization. 86
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 83
A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice 82
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study 82
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 81
Estrogen receptor alpha in peripheral blood lymphocytes of multiple sclerosis patients: a pivotal study of its role in pregnant patients 81
Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. 78
Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity 77
T HELPER 22 CELLS INCREASE IN MULTIPLE SCLEROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 76
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 76
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 76
Estrogen receptor-alpha regulates epigenetic changes on genomic regulatory regions: potential biomarkers in multiple sclerosis outcomes 75
Estrogen receptor alpha regulates key genomic regions of t-helper 17 and T-regulatory cells in Multiple Sclerosis: a new potential biomarker of disease activity. 74
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 73
Th17, an effector T Lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon beta 72
Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity 72
Epigenetic signature in T helper 17 and regulatory T cells in multiple sclerosis patients during pregnancy 72
T-helper 17 lymphocytes during MS relapses: antigen specificity and cytokine production. A multicentre longitunal study 70
Intra-tumoral IFN-gamma-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer 70
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? 69
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. 69
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 69
T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta 65
The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis 65
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 65
Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice 64
Th17 lymphocytes are expandend in multiple sclerosis and are inhibited by interferon beta 64
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-  64
T helper 22 increase in multiple sclerosis patints: phenotypical and functional characterization 57
Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their Surface Expression of IFN-γR2 57
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up 57
JAK2 is overexpressed in human multiple sclerosis Th17 cells andstabilizes cell surface expression of IFN-gammaR2. 53
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario 51
Immune Trait Shifts in Association With Tobacco Smoking: A Study in Healthy Women 50
Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome 47
Does Th17 response be harnessed by the antigen DNAvaccination against pancreatic adenocarcinomas? 46
Host genetics and gut microbiome: Perspectives for multiple sclerosis 45
T-helper 17 lymphocytes during MS relapses: antigen specifity and cytokine production. A multicentre longitudinal sudy 42
Phenotypical and functional characterization of T Helper 22 cells inMultiple Sclerosis patients 42
Six year prospective immunological study of alemtuzumab treated patients: identification of markers of the clinical response 42
Mycobacterium tuberculosis in the adjuvant modulates the balance of Th immune response to self-antigen of the CNS without influencing a "core" repertoire of specific T cells 41
Longitudinal analysis of IL-17 and/or IL-22 producing CD4+ T lymphocytes in relapsing remitting multiple sclerosis 39
Role of Th22 expansion in multiple sclerosis disease activity 39
Multiparametric analysis of Th17 and Th22 cells discloses their pathogenicity in human multiple sclerosis 38
Protective Immunity Against neu+ Carcinomas Elicited By Electroporation Of Plasmids Coding For Decreasing Fragments Of rat neu Extracellular Domain 34
JAK2 is overexpressed in human multiple sclerosis Th17 cells and stabilizes cell surface expression of IFN-gammaR2 31
A new computational workflow to guide personalized drug therapy 22
Past and future of the molecular characterization of the T cell repertoire: Some highlights of eli sercarz’s contributions 20
Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies 18
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 13
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 13
Feeding the gut microbiome: impact on multiple sclerosis 9
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it? 7
ALTERATIONS IN GUT MICROBIOME COMPOSITION ARE ASSOCIATED WITH THE ONSET AND COURSE OF MULTIPLE SCLEROSIS: AN ITALIAN COHORT STUDY 7
Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis 5
Lower Multiple Sclerosis Severity Score Is Associated with Higher Adherence to Mediterranean Diet in Subjects with Multiple Sclerosis from Northwestern Italy 2
Totale 7.007
Categoria #
all - tutte 19.155
article - articoli 0
book - libri 0
conference - conferenze 9.109
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.264


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020900 28 27 41 106 56 178 96 71 75 99 58 65
2020/2021967 73 69 42 110 104 79 71 43 98 63 79 136
2021/20221.110 36 31 40 72 63 72 78 80 48 152 232 206
2022/20231.565 147 136 48 186 141 353 110 104 186 43 72 39
2023/2024759 97 110 59 32 52 136 23 48 10 51 48 93
2024/202543 43 0 0 0 0 0 0 0 0 0 0 0
Totale 7.007